Makrilia N - Search Results

1

Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.

Charpidou A, Tsagouli S, Tsimpoukis S, Vassias A, Makrilia N, Stratakos G, Gkiozos I, Syrigos K. Charpidou A, et al. Among authors: makrilia n. Anticancer Drugs. 2010 Jul;21(6):651-5. doi: 10.1097/CAD.0b013e3283393718. Anticancer Drugs. 2010. PMID: 20386306 Clinical Trial.

2

Hypersensitivity reactions to antineoplastic agents: an overview.

Syrigou E, Makrilia N, Koti I, Saif MW, Syrigos KN. Syrigou E, et al. Among authors: makrilia n. Anticancer Drugs. 2009 Jan;20(1):1-6. doi: 10.1097/CAD.0b013e32831961b3. Anticancer Drugs. 2009. PMID: 19342995 Review.

3

Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.

Ralli M, Tourkantonis I, Makrilia N, Gkini E, Kotteas E, Gkiozos I, Katirtzoglou N, Syrigos K. Ralli M, et al. Among authors: makrilia n. Anticancer Res. 2009 Aug;29(8):3441-4. Anticancer Res. 2009. PMID: 19661370 Free article. Clinical Trial.

4

Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?

Syrigou E, Makrilia N, Vassias A, Nikolaidis I, Xyla V, Manolopoulos L, Syrigos K. Syrigou E, et al. Among authors: makrilia n. Anticancer Drugs. 2010 Mar;21(3):333-8. doi: 10.1097/CAD.0b013e32833418c0. Anticancer Drugs. 2010. PMID: 20038831

5

Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.

Katirtzoglou N, Gkiozos I, Makrilia N, Tsaroucha E, Rapti A, Stratakos G, Fountzilas G, Syrigos KN. Katirtzoglou N, et al. Among authors: makrilia n. Clin Lung Cancer. 2010 Jan;11(1):30-5. doi: 10.3816/CLC.2010.n.005. Clin Lung Cancer. 2010. PMID: 20085865 Clinical Trial.

6

Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.

Tourkantonis I, Makrilia N, Ralli M, Alamara C, Nikolaidis I, Tsimpoukis S, Charpidou A, Kotanidou A, Syrigos K. Tourkantonis I, et al. Among authors: makrilia n. Am J Clin Oncol. 2011 Feb;34(1):38-42. doi: 10.1097/COC.0b013e3181cae90e. Am J Clin Oncol. 2011. PMID: 20142722 Clinical Trial.

7

Cell adhesion molecules: role and clinical significance in cancer.

Makrilia N, Kollias A, Manolopoulos L, Syrigos K. Makrilia N, et al. Cancer Invest. 2009 Dec;27(10):1023-37. doi: 10.3109/07357900902769749. Cancer Invest. 2009. PMID: 19909018 Review.

8

Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol.

Syrigou E, Dannos I, Kotteas E, Makrilia N, Tourkantonis I, Dilana K, Gkiozos I, Saif MW, Syrigos KN. Syrigou E, et al. Among authors: makrilia n. Int Arch Allergy Immunol. 2011;156(3):320-4. doi: 10.1159/000324454. Epub 2011 Jun 29. Int Arch Allergy Immunol. 2011. PMID: 21720178

9

Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.

Makrilia N, Syrigos KN, Saif MW. Makrilia N, et al. JOP. 2011 Jul 8;12(4):351-4. JOP. 2011. PMID: 21737894 Free article. Review.

10

Acute hypersensitivity reactions to chemotherapy agents: an overview.

Syrigou E, Triantafyllou O, Makrilia N, Kaklamanos I, Kotanidou A, Manolopoulos L, Syrigos K. Syrigou E, et al. Among authors: makrilia n. Inflamm Allergy Drug Targets. 2010 Jul;9(3):206-13. doi: 10.2174/187152810792231887. Inflamm Allergy Drug Targets. 2010. PMID: 20632960 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters